Top

Clinical & Experimental Metastasis

Published in:

01-11-2006 | Original Paper

Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-β pathway

Authors: Arianna Nicolussi, Sonia D’Inzeo, Angela Gismondi, Anna Coppa

Published in: Clinical & Experimental Metastasis | Issue 5-6/2006

Title: Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-β pathway
Authors: Arianna Nicolussi
Sonia D’Inzeo
Angela Gismondi
Anna Coppa
Publication date: 01-11-2006
Publisher: Kluwer Academic Publishers
Published in: Clinical & Experimental Metastasis / Issue 5-6/2006
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-006-9023-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 5-6/2006

Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

Neutrophil activator of matrix metalloproteinase-2 (NAM)

Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells

Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase

Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer